Corporate Presentation · ... , food additives, cosmetics, food safety and more. ... the Coca Cola Company in 2001 ... Southeast Asia and China

CorporatePresentation

January,2017

CompanyOverviewZIVOBioscience,Inc.(OTCMKTS:ZIVO)developsandcommercializesnutritionalcompoundsandbioactivemoleculescreatedbyitsproprietaryalgalstrains

§ Companyistargetingthefollowingapplications:o DietarySupplements,NutraceuticalsandFoodIngredientso AnimalFeed,DietarySupplements&AnimalDrugDevelopmento Pharmaceuticals

ZIVOQuickFacts:§ MarketCapitalizationof$15M(asofJanuary4,2017)§ Pre-RevenueStatus§ HeadquartersinKeegoHarbor,Michigan(UnitedStates)

§ Near-TermRevenueOpportunity - ZIVOexecutedacollaborationagreementDecember2013withZoetis(formerlyPfizerAnimalHealth),theworld’slargestanimalhealthcompanyforbovinemastitisresearch

§ IntellectualPropertyPortfolio – ZIVOholds 4issuedpatentsandanother9applicationsinprocess

§ OtherLifeSciences -- ZIVOalsoholdsvaluableinnovationsinmetabolictestingforhumansandanimals– WellMetrisisabreakthrough,smartphone-enabledtestingplatformthatprovidesunprecedentedinsightsintohealthandnutrition

PhotocourtesyofArizonaCenterforAlgaeTechnology&Innovation

RecentNews&EventsZIVOhasannounced3majornewseventsrecently,andcontinuestomakeprogresstocommercializeitsworld-classIPportfolio.

GrowingtheIPPortfolio

November17,2016-- ZIVOannouncesthatitreceivednoticeofafourthUSpatentcoveringthenovelcholesterolmanagementproperties ofthebioactivecomponentsextractedfromitsproprietaryalgalculture

NewProteinProductConcept

NewJVinPoultryFeedAdditives

November9,2016– ZIVOunveilsanew,high-proteinveganpowerdrinkconcept containingCompany'sproprietaryalgalbiomassinfinepowder.Asignificantsourceofnon-animal,non-dairy,non-GMOveganproteinanddietaryfiber

December15,2016– ZIVOannouncesanagreementinprinciplewithanimalnutritioninnovatorNutriQuesttodevelopapoultryfeedadditiveforimmunehealth andgrowthpromotion.WorkbeginsinFebruary,2017

AlgaeQuickFactsAlgaeareadiversegroupofaquaticorganismsthathavetheabilitytoconductphotosynthesis

§ Theylooksimilartolandplants,butdonothavethedistinctcellandtissuetypes,suchasstomata,xylem,andphloem

§ Mostrecentestimatessuggests72,500algalspeciesworldwide

§ Manycommercialusesforalgae,including:

o Nutrition - animal/fishfeed,humansupplements,foods

o Medical – usesintopicalcreams,andpharmaceuticalcompounds

o Specialtychemicals – agrochemicals,foodadditives,cosmetics,foodsafetyandmore

ManagementSeniormanagementatZIVOhasexperienceincapitalformation,finance,biotech,biomedicalengineeringandcollaboratingwithlargercommercialentities

AndrewA.DahlChiefExecutiveOfficer&President

• Formerlymanagingmemberof GreatNorthern&ReservePartners,amanagementconsultingfirm providing marketingandbusinessconsultingtobiotech,biomedandITcompanies

• FormerPresidentofDawber&Company,oneoftheoldestandlargestindependentmarketing&consultingfirmsintheMidwest. ExtensiveFortune500clientroster– GM,Ford,AT&T,CompuwareandXerox,amongothers

• AttendedCollegeforCreativeStudies, WayneStateUniversity• Holds three US patents for interactive multimedia and named inventor in eightrecent biomedical patent applications

John B.PayneVice-Chairman,BoardofDirectors

• President&CEOofCompassionFirst,anationwidenetworkofspecialtyveterinaryhospitals.CurrentlyChairman,AmericanHumaneAssociation

• FormerCEOofBanfieldPetHospitals,anationwide800-hospitalchain• Formerly,memberofMarsGlobalPetCareleadershipteamrepresentingover$11billioninanimalhealthrevenuesannually

• Formerly PresidentofBayerNorthAmericaAnimalHealthdivision• MBA,RockhurstUniversity

Management

Amy E.SteffekPhDDirector,Research&Development

• Currently managingallscienceandproductdevelopmentatZIVO• Previously consultedtolifesciencecompaniestodeveloppharmaproducts,medicaldevices,medicalITproducts

• 14yearsofscientificresearchspanningneurology,cardiology,oncology,psychiatryandendocrinology

• PhD inNeuroscience,UniversityofMichigan– AnnArbor• Postdoctoral fellowshipsintranslationalmedicineandneuroendocrinology,UniversityofMichigan– AnnArbor

• Named inventorinseveralbiomedicalpatentapplications

SeniormanagementatZIVOhasexperienceincapitalformation,finance,biotech,biomedicalengineeringandcollaboratingwithlargercommercialentities

Kerry W.WilsonDirector,EngineeringProjectManagement

• Currently managingengineeringandprojectplanningatZIVO• Formerlyadjunctprofessor,UniversityofNotreDame,lifescienceentrepreneurialstudiesandconsultanttoNotreDamestartups

• FormerlyDirectorofEngineering,HandyLab,Inc.andlead developeroflab-on-a-chiptechnologyplatform.

• FormerlyManager,BayerDiagnosticsBusinessDevelopmentandProductManagerforUrineChemistryMarketing

• BAinPhysics,WabashCollege– Crawfordsville,IN• BS inEngineering,ColumbiaUniversity– NewYork,NY

PlatformStrategyTheZIVOBusinessModel

§ TobecomealicensorofdevelopedIPofproprietaryalgaecultures,extractsandderivatives.workingwithtwodifferenttypesofpartners

§ Near-Termpartners- canusetheZIVOIPandgettomarketquickly– inanimalhealth,humandietarysupplementsandfunctionalfoods

§ Longer-Termpartners- pharmaceuticalcompanies

ZIVOCoreIntellectualProperty

§ Proprietary,optimizedalgaestrains§ Patentedprocessofproducingbioactivecompounds§ Nutritiveorbioactivecomponentsextracts,and§ Applicationofthatstrain/extractinsupportinghealthandlongevity

World-ClassResearch&Validation

§ PotentialpartnersandlicenseesrequireproofthatZIVO’snutritionalandactivecomponentsdeliveronclaims

§ Overlastfouryears,ZIVOhasengagedinavarietyofvalidation,safety,interactions,andstabilityteststoprovesuchclaims,andmeetcomplianceregulationssetforthbytheFDA,USDA,EPA,andFTC

PhotocourtesyofArizonaCenterforAlgaeTechnology&Innovation

Food,Farming&theFutureTheCompany’salgalbiomass,secondarymetabolitesandextractsmaybedevelopedintoingredientsforthesemarketverticals

§ DietarySupplement/Nutraceutical

o AccordingtoTransparencyMarketResearch,theglobalnutraceuticalsmarketwillbe$279Billionby2021

o USandworldwideopportunitiesincludespirulina,algae-derivedOmega-3s,algae-derivedastaxanthin,driedkelp,etc.

§ FunctionalFoodIngredient

o Over400good-for-youfoodandbeveragecategoriesneedpowerfulingredientstosupporttheirproductclaims

o Dozensoflicensescanbecreated

§ Pharmaceuticals

o Aspotentialleadcompoundsfordrugdevelopment

ZIVOisindiscussionswithmajorpartnerstoproposejointventures

NewVeganProteinProductConceptInNovember2016,ZIVOunveiledanew,high-proteinveganpowerdrinkConcepttocompeteinveggiesmoothieandveganpowerdrinkcategories

§ VegetableandfruitjuicebeveragecontainstheCompany'sproprietaryalgalbiomass,driedtoafinepowder,providesasignificantnon-animal,non-dairy,non-GMO,antibiotic-freesourceofveganprotein

§ Thisnewproductconceptisintendedtodisplaceothervegetableandsoybasedproteindrinks- asignificantglobalmarketo Unlikesomeothercultivatedalgae,theZIVOstrainisessentially

blandandmixeswellwithsweetorsavoryflavorso Thetwoflavorsindevelopmentfeatureasweet,pomegranatefinish

andtheotheramoresavory,vegetablefinish

§ ZIVOalgaebiomassrepresentsapotentiallyviablealternativetoothersourcesofhigh-qualityprotein,onceapprovedforsaleo Earlyformulationsboastastandout42gramsofplant-basedprotein

per15-ounceservinginacategorywheretheaverageis8orlesso A100- gram(3oz.)portionprovides42gramsofproteinand24

gramsoffiber,whiledeliveringmoreVitaminCthanamedium-sizedorange,andmoreVitaminAthan3-1/2oz.ofbeefliver

ZIVOVeganPowerDrinkvsCompetitionTheZIVOhigh-proteinveganpowerdrinkcomparesfavorablytootherentriesinveggieshake,smoothiemixandready-to-drinkcategories,offeringhigherproteincontent,vitamins,fiberandotherhealthbenefits.

MarketOpportunity

Strongdemandforgluten-free,dairy-free,antibiotic-free,non-GMO,plant-basedproteinvegansmoothies

ZIVOMegatein(12ozserving)* NakedPressed HeartyGreens(12oz)**Protein § 18g Protein § 3g

DietaryFiber § 6g DietaryFiber § 0g

VitaminA § 59%DV VitaminA § 0%DV

VitaminC § 34%DV VitaminC § 25% DV

Iron § 12%DV Iron § 2%DV

Calcium § 9%DV Calcium § 4% DV

*Preliminaryproductspecificationspendingregulatoryapprovalandformulationtesting

**Productspecificationsderivedfrombottlelabeling

FastestGrowingBeverageCategoryThefruitjuice/refrigeratedsmoothiecategorywasthefastestgrowingbeveragecategoryin2015.§ Accordingtothemarketresearchfirm,Technavio,theGlobalsmoothiesmarketwillbe$7Billionby2020.

MarketShare:FruitDrinksandFruitJuices(C-storesales|2015)Sub-Category DollarShare %GrowthY-o-YRTDTea 5.60% -6.60%RTDCoffee 2.70% -10.00%Water 12.80% 4.60%Others 2.20% 3.80%Sportsdrinks 9.90% 2.10%Energydrinks 27.70% 9.50%Fruitdrinks 4.40% 14.30%Carbonatedsoftdrinks 31.10% 23.30%Fruitjuices 3.40% 94.00%Sources:TheNielsenCo.,Dr.PepperSnappleGroupInc.

NakedJuicewasacquiredbyPepsiCoin2007.

Odwalla Inc.wasacquiredbytheCocaColaCompanyin2001

Megatein hastheopportunitytobedisruptiveinthisbeveragecategorybecauseitcontainmoreproteinandessentialvitamins

ZIVOVeganProteinvsCompetitionTheZIVOveganproteindrink/mixcomparesfavorablytootherentriesinproteindrinkmixandready-to-drinkcategories,offeringhighqualityproteincontent,vitamins,fiberandotherhealthbenefits

MarketOpportunity

AccordingtoaEuromonitor 2016ReportonSportsNutrition,thesportsproteinpowderdrinksmarketwillbe$4.7Billionby2020

ZIVOMegatein*(100grams) MuscleMilk**(100grams)

Protein § 43g Protein § 46g

DietaryFiber § 24g DietaryFiber § 7g

VitaminA § 200%DV VitaminA § 5%DV

VitaminC § 110%DV VitaminC § 30% DV

Iron § 80%DV Iron § 90%DV

Calcium § 9%DV Calcium § 50% DV

*Natural,non-concentratedalgalbiomassasingredient**Preliminaryproductspecificationspendingregulatoryapprovalandformulationtesting

*Milkwheyconcentratedwithsolvents**Productspecificationsderivedfrombottlelabeling

HumanHealth- ResearchTheCompany’sproprietaryalgalcultureextractswerefoundtobebeneficialinpre-NDI/pre-INDstudiesasappliedtohumanandhypercholesterolemichamstermodels

§ In-vivotestingofhypercholsterolemiaatWayneStatueUniversityDept.ofNutritionandFoodSciencefoundtestsubjectstreatedwithcultureextractsdroppedtotalcholesterolby32%andincreasedHDLcholesterolcountsby5%instudiesconducted2009-2012

§ In-vitrotestingofhumanHEP-G2andPBMCcelllinesrevealedearlypromiseinaddressinginflammatorycascadesresultingfromlipidperoxidationinrepeatedstudiesatWayneStateUniversitySchoolofMedicineconducted2010-2012

§ Companycommencedisolationandcharacterizationeffortsofbioactivecomponentsin2014aspotentialcholesterolmanagement,autoimmuneandanti-inflammatoryingredientsinhumanfoodanddietarysupplements

§ UponcompletionofsafetytrialsandGRAScertification,ZIVOintendstolicensetheuseofbioactivecomponentsinavarietyofhealthandnutritionapplicationsforhumanandanimaluse

AnimalHealthOpportunityNear-TermFocus– ZIVO’sproprietary,algae-derivedbioactivecompoundswerefoundtobeeffectiveinearlystudieswhenappliedtodairycattleanddogmodels

DairyCows&BovineMastitis

§ AZIVOpilotstudyindairycowsindicatedthattheCompany’salgalculturemaybeeffectiveinsupportingbovinemammaryglandhealth

§ Mammaryglandissuesaffect10%oftheU.S.dairyherdatanygiventime,costingproducersasmuchas$300peroccurrence,peranimal.IntheU.S.alone,productionlossesarenear$3billionannually(1)

Dogs&Osteoarthritis

§ AZIVOpilotstudyindicatedthattheCompany’salgalculturemaybeeffectiveinmaintainingproperjointfunctionandsupportinghealthymusclefunctioninginactivedogsandslowingthedegenerativeeffectsofcanineosteoarthritis.

§ Caninedietarysupplementindustrytops$10billionintheU.S.alone

§ Caninejointhealthsupplementsisa$300millionmarketintheUSalone

(1) DatafromtheNationalMastitisCouncil

AnimalHealthOpportunity– ZoetisCollaborationTheCompanyenteredintoaconfidentialCollaborationandOptionAgreementwithZoetis,aglobalanimalhealthcompany

Zoetis,Inc.istheworld'slargestproducerofmedicineandvaccinationsforpetsandlivestock

§ ZoetiswasasubsidiaryofPfizer,theworld'slargestdrugmaker§ NowanindependentcompanyandtradesasNYSE:ZTS,witha$24BillionMarketCapitalizationandamemberofS&P500Index

§ Operatesin70countriesworldwidewithrecentexpansionsintoSoutheastAsiaandChina

Theagreementwascreatedtostudytheprevention,treatment,andmanagementofbovinemastitis

§ IntheAgreement,ZIVOgrantedtoZoetisanexclusiveoptiontonegotiateanexclusivelicense

§ Uponcompletionofacollaborativestudy(whichisinprocessandwillbecompleteduponadequatefunding),theAgreementprovidesfora90dayexclusivityperiodforevaluationofresultsand,basedonthecounterparty’sdesireforanexclusivelicensethereto,90daystoconcludeanexclusivelicenseagreement

NewJVOpportunityinPoultryFeedAdditivesZIVOandNutriQuest haveenteredintoanagreementinprincipletodevelopandmarketanimalnutritionproductsforimmunehealthandproductivityenhancement

§ Jointlyconductproof-of-conceptstudiestosubstantiatenutritionandhealthclaims§ ZIVOtoproduceandNutriQuesttomarketapoultryfeedadditive,followedbyswineandcattle§ NutriQuestoperatesin20countries,providingnutrition/healthsolutionstopoultryandporkproducers

MarketOpportunity

Launchacategory-dominatingproductinarapidlygrowingsegmentoftheglobalanimalfeedadditiveindustry

NutriQuest andZIVOPotentialPartnershipStructureZIVO Bioscience,Inc. § Funds proof-of-conceptpoultry,swinestudies

§ Responsible forproductformulationandproduction

NutriQuest,LLC § Conducts proof-of-conceptpoultry,swinestudies§ Marketsanddistributes finishedproductsglobally

ZIVOandNutriQuesttosplitgrossmargin50/50overcostofgoodssold

PoultryFeedAdditiveMarketLandscape

MarketOpportunity

Theglobalanimalfeedadditivemarketisexpectedtoreach$27billionby2021ataCAGRof6.5%peryear1

ZIVOanimalhealthproductsarepositionedasimmunehealthandproductivityenhancers

§ Non-starchpolysaccharidesareavaluablepromoterofdigestivehealthandimmuneresponse§ Producersareabletocutbackontheuseofantibioticsinfeedanduselower-costfeedingredients

PoultryFeedAdditiveFactsGlobal PoultryAdditiveMarket § Expected toreach$7.8billionby2018

GlobalPhytogenicFeedAdditives § This segmenttoreach$675millionby2020

LargestMarketsforPhytogenics § EU andUSlargestpurchasersofphytogenicfeeds

ZIVOPoultryFeedAdditive § Potential tobecategoryleader

(1) AlliedMarketResearch,"World AnimalFeedAdditives Market-Opportunities andForecasts,2014-2021”.

ZIVOandNutriQuest intendtoobtainregulatoryapproval,securebiomassproductionofftakeagreementsandinitiallyenterthemarketwithasinglepoultryfeedadditiveproduct

AnimalHealth– ResearchTheCompany’sproprietaryalgalculture,itsextractsandisolates,arefoundtobeeffectiveinpre-NDIstudiesasappliedtodairycattleanddogmodels

§ In-vitrotestingofprimarybovinemammaryepithelialcellsin3DcultureatUniversityofWisconsin-MadisonDept.ofDairyScienceindicatedenhancedimmuneresponsewhencellswereexposedtoinfectivepathogensresponsibleforbovinemastitis,2013-2014

§ ExplanttestingofcaninejointtissuesatUniversityofMissouriComparativeOrthopaedicLaboratoryhasindicatedtheCompany’sbioactivecompoundsmayslowthedegenerativeeffectsofcanineosteoarthritis,2014

§ DairycowmastitisinvivopilotstudyatUC-Davisyieldedveryimpressiveresultsincombattingmycoplasmabovis.AspartofitsongoingcollaborationagreementwithZoetis,formerlyPfizerAnimalHealth– world’slargestanimalpharmacompany,theCompanydeliveredapilotstudyreportinspring,2015

ZIVOtoconcludesafety/efficacytestinginordertoobtainregulatoryapprovaltoformulateandmarketproducts.Dairycattleandpoultryarethetwoinitialtargetspecies

AcquiringOtherIntellectualPropertyAcquiredassetsofmetabolictestingcompanyinAugust2013– WellMetrisisasubsidiarycurrentlyinFDApre-submission,preparingformarketlaunchandactivepartnering

§ WellMetrisdevelops,manufactures,marketsandsellsWellnessTestsforhumansandanimals

§ TheWellnessTestsareintendedtoprovideindividualstheinformationandopportunitytooptimizetheirhealthandidentifyfuturehealthrisksortoprovideinsurers,employersandhealthcareproviderstimelyinformationtointervenewithwellnessprograms,fitnessregimesorotherpreventativemeasures

§ ZIVO/WellMetrishavefiledanddraftedanadditionaleightpatentapplications

Capitalization/OwnershipTableCompanyhasashareholderbasethatbelievesinZIVO’snear-termandlong-termprospects

OwnershipTable (asofOctober13th,2016)Holder #ofShares %OfCSODirectors&Officers 24,646,415 18%PublicFloat 111,570,361 82%Total 136,216,776 100%

CapitalizationTable WeightedAverageSecurity CommonStockEquivalentHeld Conversion/ExercisePriceCommonStock 136,216,776ConvertibleDebt 102,122,573 $0.12Warrants 29,267,488 $0.10

FullyDilutedSharesOutstanding 267,606,837

UpcomingMilestonesManagementofZIVOlooksforwardtoannouncingoverthenextseveralmonths,thefollowingtypesofnewsannouncements,pendingavailablefunding

§ ZIVOtoconcludethefinalphasesofitscollaborativestudywithZoetis,andbeginnegotiatinganoption/licensingdeal

§ ZIVOconductingsafetystudiesforhumanFDAapprovalofitsalgalbiomassandextractsasfoodingredientsanddietarysupplementingredients

§ ZIVOconductinganalyticstudiesatUniversityofGeorgiatofullycharacterizetheactiveingredientsinitsproprietaryalgalextract

§ ZIVOtoconductproductdevelopmentwithNutriQuestLLCtomarketalgae-basedpoultryandpigfeedingredients

§ ZIVOlookstoexpandproductioncapacityinsouthernCaliforniaorSouthwestareas

InvestmentHighlights

§ $13M(1) Equity Valuerepresentscompellingbuyingopportunity

§ Near-TermcommercializationopportunitywithZoetis–pendingstudy

§ Majoropportunityinhumanhealth/ nutraceuticalproductionbeingpursued

(1)EquityValueasofJanuary4,2017

CorporatePresentation– January,2017

PleaseContact:

ZIVO Bioscience,Inc.2804OrchardLakeRoadSuite202KeegoHarbor,MI48320Office:248.452.9866ext.150Email:[email protected]:www.zivobioscience.com